172 related articles for article (PubMed ID: 19577936)
1. Pioglitazone, but not metformin, reduces liver fat in Type-2 diabetes mellitus independent of weight changes.
Gupta AK; Bray GA; Greenway FL; Martin CK; Johnson WD; Smith SR
J Diabetes Complications; 2010; 24(5):289-96. PubMed ID: 19577936
[TBL] [Abstract][Full Text] [Related]
2. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
Gupta AK; Smith SR; Greenway FL; Bray GA
Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
[TBL] [Abstract][Full Text] [Related]
3. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts).
Raskin P; Matfin G; Schwartz SL; Chaykin L; Chu PL; Braceras R; Wynne A
Diabetes Obes Metab; 2009 Jan; 11(1):27-32. PubMed ID: 17941873
[TBL] [Abstract][Full Text] [Related]
4. Metabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group study.
Mattoo V; Eckland D; Widel M; Duran S; Fajardo C; Strand J; Knight D; Grossman L; Oakley D; Tan M;
Clin Ther; 2005 May; 27(5):554-67. PubMed ID: 15978304
[TBL] [Abstract][Full Text] [Related]
5. [Six-month effectiveness and tolerability of pioglitazone in combination with sulfonylureas or metformin for the treatment of type 2 diabetes mellitus].
Rodríguez A; Reviriego J; Polavieja P; Mesa J
Med Clin (Barc); 2008 Nov; 131(19):721-30. PubMed ID: 19091199
[TBL] [Abstract][Full Text] [Related]
6. Effect of pioglitazone on energy intake and ghrelin in diabetic patients.
Martin CK; Gupta AK; Smith SR; Greenway FL; Han H; Bray GA
Diabetes Care; 2010 Apr; 33(4):742-4. PubMed ID: 20067964
[TBL] [Abstract][Full Text] [Related]
7. Effects of pioglitazone versus glimepiride exposure on hepatocellular fat content in type 2 diabetes.
Phielix E; Brehm A; Bernroider E; Krssak M; Anderwald CH; Krebs M; Schmid AI; Nowotny P; Roden M
Diabetes Obes Metab; 2013 Oct; 15(10):915-22. PubMed ID: 23574533
[TBL] [Abstract][Full Text] [Related]
8. Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients.
Bajaj M; Suraamornkul S; Piper P; Hardies LJ; Glass L; Cersosimo E; Pratipanawatr T; Miyazaki Y; DeFronzo RA
J Clin Endocrinol Metab; 2004 Jan; 89(1):200-6. PubMed ID: 14715850
[TBL] [Abstract][Full Text] [Related]
9. The effect of pioglitazone on glycemic and lipid parameters and adverse events in elderly patients with type 2 diabetes mellitus: a post hoc analysis of four randomized trials.
Rajagopalan R; Xu Y; Abbadessa M;
Am J Geriatr Pharmacother; 2006 Jun; 4(2):123-33. PubMed ID: 16860259
[TBL] [Abstract][Full Text] [Related]
10. Management of cardiovascular risk factors with pioglitazone combination therapies in type 2 diabetes: an observational cohort study.
Rodríguez A; Reviriego J; Karamanos V; del Cañizo FJ; Vlachogiannis N; Drossinos V;
Cardiovasc Diabetol; 2011 Feb; 10():18. PubMed ID: 21314919
[TBL] [Abstract][Full Text] [Related]
11. Effects of combined exenatide and pioglitazone therapy on hepatic fat content in type 2 diabetes.
Sathyanarayana P; Jogi M; Muthupillai R; Krishnamurthy R; Samson SL; Bajaj M
Obesity (Silver Spring); 2011 Dec; 19(12):2310-5. PubMed ID: 21660077
[TBL] [Abstract][Full Text] [Related]
12. Double-blind, randomized, multicentre, and active comparator controlled investigation of the effect of pioglitazone, metformin, and the combination of both on cardiovascular risk in patients with type 2 diabetes receiving stable basal insulin therapy: the PIOCOMB study.
Hanefeld M; Pfützner A; Forst T; Kleine I; Fuchs W
Cardiovasc Diabetol; 2011 Jul; 10():65. PubMed ID: 21756323
[TBL] [Abstract][Full Text] [Related]
13. Pioglitazone in addition to metformin improves erythrocyte deformability in patients with Type 2 diabetes mellitus.
Forst T; Weber MM; Löbig M; Lehmann U; Müller J; Hohberg C; Friedrich C; Fuchs W; Pfützner A
Clin Sci (Lond); 2010 Jul; 119(8):345-51. PubMed ID: 20509857
[TBL] [Abstract][Full Text] [Related]
14. Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, mechanistic study.
Tripathy D; Daniele G; Fiorentino TV; Perez-Cadena Z; Chavez-Velasquez A; Kamath S; Fanti P; Jenkinson C; Andreozzi F; Federici M; Gastaldelli A; Defronzo RA; Folli F
Diabetologia; 2013 Oct; 56(10):2153-63. PubMed ID: 23811853
[TBL] [Abstract][Full Text] [Related]
15. Pioglitazone elicits long-term improvements in insulin sensitivity in patients with type 2 diabetes: comparisons with gliclazide-based regimens.
Charbonnel B; Roden M; Urquhart R; Mariz S; Johns D; Mihm M; Widel M; Tan M
Diabetologia; 2005 Mar; 48(3):553-60. PubMed ID: 15739120
[TBL] [Abstract][Full Text] [Related]
16. The comparative effect of pioglitazone and metformin on serum osteoprotegerin, adiponectin and intercellular adhesion molecule concentrations in patients with newly diagnosed type 2 diabetes: a randomized clinical trial.
Esteghamati A; Azizi R; Ebadi M; Noshad S; Mousavizadeh M; Afarideh M; Nakhjavani M
Exp Clin Endocrinol Diabetes; 2015 May; 123(5):289-95. PubMed ID: 25607338
[TBL] [Abstract][Full Text] [Related]
17. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone.
Wajcberg E; Sriwijitkamol A; Musi N; DeFronzo RA; Cersosimo E
J Clin Endocrinol Metab; 2007 Apr; 92(4):1256-62. PubMed ID: 17244785
[TBL] [Abstract][Full Text] [Related]
18. Effects of pioglitazone and metformin on intracellular lipid content in liver and skeletal muscle of individuals with type 2 diabetes mellitus.
Teranishi T; Ohara T; Maeda K; Zenibayashi M; Kouyama K; Hirota Y; Kawamitsu H; Fujii M; Sugimura K; Kasuga M
Metabolism; 2007 Oct; 56(10):1418-24. PubMed ID: 17884455
[TBL] [Abstract][Full Text] [Related]
19. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
[TBL] [Abstract][Full Text] [Related]
20. Exenatide decreases hepatic fibroblast growth factor 21 resistance in non-alcoholic fatty liver disease in a mouse model of obesity and in a randomised controlled trial.
Samson SL; Sathyanarayana P; Jogi M; Gonzalez EV; Gutierrez A; Krishnamurthy R; Muthupillai R; Chan L; Bajaj M
Diabetologia; 2011 Dec; 54(12):3093-100. PubMed ID: 21956711
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
